AKLRD identifies and synthesizes secondary metabolites of plant origin with proven efficacy & safety. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.
The development process is led by an expert management team with a high level of technical, scientific and strategic skill.
AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.
AKLRD is based at the Stevenage Bioscience Catalyst, Stevenage, Herts UK.